Biological resurfacing in a canine model of hip osteoarthritis by Estes, Bradley T et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
Biological resurfacing in a canine model of hip osteoarthritis 
Bradley T Estes 
Masataka Enomoto 
Franklin T Moutos 
Megan A Carson 
Jeffrey M Toth 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Bradley T Estes, Masataka Enomoto, Franklin T Moutos, Megan A Carson, Jeffrey M Toth, Peter Eggert, 
Jonathan Stallrich, Vincent P Willard, Deborah J Veis, Dianne Little, Farshid Guilak, and B Duncan X 
Lascelles 
Estes et al., Sci. Adv. 2021; 7 : eabi5918     15 September 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 13
H E A L T H  A N D  M E D I C I N E
Biological resurfacing in a canine model of  
hip osteoarthritis
Bradley T. Estes1*†, Masataka Enomoto2†, Franklin T. Moutos1, Megan A. Carson3, Jeffrey M. Toth4, 
Peter Eggert4, Jonathan Stallrich5, Vincent P. Willard1, Deborah J. Veis6,7,8, Dianne Little9, 
Farshid Guilak1,7,10,11*‡, B. Duncan X. Lascelles2,12,13,14*‡
Articular cartilage has unique load-bearing properties but has minimal capacity for intrinsic repair. Here, we used 
three-dimensional weaving, additive manufacturing, and autologous mesenchymal stem cells to create a tissue- 
engineered, bicomponent implant to restore hip function in a canine hip osteoarthritis model. This resorbable 
implant was specifically designed to function mechanically from the time of repair and to biologically integrate 
with native tissues for long-term restoration. A massive osteochondral lesion was created in the hip of skeletally 
mature hounds and repaired with the implant or left empty (control). Longitudinal outcome measures over 6 months 
demonstrated that the implant dogs returned to normal preoperative values of pain and function. Anatomical 
structure and functional biomechanical properties were also restored in the implanted dogs. Control animals never 
returned to normal and exhibited structurally deficient repair. This study provides clinically relevant evidence 
that the bicomponent implant may be a potential therapy for moderate hip osteoarthritis.
INTRODUCTION
Osteoarthritis (OA) is a degenerative disease affecting all components 
of the joint, characterized by progressive damage to the articular 
cartilage and underlying bone. While the primary treatment for 
end-stage OA is a total joint replacement, long-term follow-up 
studies show that up to one-third of patients under the age of 40 at 
the time of total hip arthroplasty have loosening or excessive wear 
problems later in life (1). Thus, any procedures that serve to postpone 
joint replacement and preserve the joint would have a substantial 
clinical benefit. However, alternative biologic techniques, such as 
osteochondral transfer or microfracture procedures, are ineffective 
for larger lesions (2, 3). Second-generation autologous chondrocyte 
implantation or matrix-assisted chondrocyte implantation procedures 
are not approved for use outside the knee joint and report an almost 
30% failure rate within 9 years in young patients (4–6). There is a 
need for improved techniques, implants, and procedures to effectively 
treat the disease or, at a minimum, delay the progression of OA 
to the point at which the patients are better candidates for a hip 
arthroplasty procedure.
In our previous work, we have developed a unique cartilage repair 
implant using a textile manufacturing process of three-dimensional 
(3D) orthogonal weaving to form a construct that is biomechanically 
and biologically designed for cartilage repair (7–11). One of the 
principal advantages of this biomimetic structure is that it enables 
the implantation of a device that has been optimized to support the 
loads in the joint while providing a conduit for endogenous cell 
infiltration, tissue synthesis, and integration with native tissues for 
long-term functional support (12). This approach is in direct con-
trast to the use of many biomaterials used to date for cartilage tissue 
engineering, which do not have the mechanical properties and 
load-bearing characteristics of native cartilage until significant 
matrix deposition has occurred over time. The basis of this technology 
is a 3D “microweave” of fibers in three orthogonal directions. In 
comparison to standard weaving methods, this process eliminates 
fiber crimp and forms a true 3D structure that can be tuned in tension, 
compression, and shear to match native cartilage properties. Most 
current 3D textile composite materials are constructed by laminating 
multiple 2D structures together; here, the use of a true 3D woven 
structure eliminates the weak interfaces between multiple layers in 
the structure, where delamination can occur. Furthermore, the con-
trolled regularity and interconnectivity of the woven pore structure 
allow cells to be easily loaded and uniformly distributed within the 
scaffold upon which they are able to synthesize a robust extracellular 
matrix (Fig. 1) (7, 9, 10, 13). The regular pore geometry also facili-
tates nutrient diffusion along regular and continuous paths through-
out the scaffold (7). These properties have been optimized to mimic 
the functional properties of articular cartilage and have demon-
strated their ability to sustain functional properties over extended 
in vitro culture (7, 9, 10, 13). To enhance stable integration of the 
3D woven textile into the bone bed, an additively manufactured porous 
base has also been integrated into the implant (Fig. 1, F and G). This 
type of structure has been shown in previous work to promote 
osteogenesis of transplanted stem cells by stimulating signaling 
pathways that enhance osteogenesis (14).
The objective of this work was therefore to test the ability of this 
bicomponent tissue-engineered construct to replace most of the 
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load-bearing cartilage surface of the femoral head in a large animal 
model, using autologous bone marrow–derived mesenchymal stem 
cells (MSCs) on an anatomically shaped 3D woven scaffold (7, 10, 11). 
Our hypothesis was that a scaffold engineered to mimic many of the 
mechanical properties of the native tissue with sufficient porosity 
for cell ingrowth and tissue differentiation (7–9, 11) could restore 
the articular surface structure and, thereby, also restore normal 
function to the joint. To test this hypothesis, we used a canine model 
of hip OA, because of its similarities in the human hip, and collected 
quantitative functional outcome data longitudinally throughout the 
6-month duration of the study (15–17). The bicomponent nature 
of the 3D woven textile and additively manufactured base enable 
a novel treatment paradigm for osteochondral repair for large le-
sions that cannot be repaired with current bone marrow stimula-
tion techniques.
RESULTS
Outcome measures in this study were primarily focused on behav-
ioral measures of joint pain and function (i.e., gait analysis), with 
concomitant analysis of the structural integrity and mechanical 
properties of the regenerated tissues at the 6-month termination of 
the study.
Gait analysis, limb girth, pain, and actimetry
The implant group trended toward baseline in all gait analysis mea-
sures and was also found to return to baseline in three of the five 
measures (Fig. 2). For peak vertical force (PVF), which is one of the 
principal components for quantifying lameness, the implant group 
indicated better limb use, quantified as 6.82 ± 2.23% body weight 
(BW) larger than the control group’s average across all time points 
(Fig. 2A). The animals receiving the implant returned to baseline 
PVF by month 3. For vertical impulse (VI), another principal mea-
sure for quantifying lameness, the implant group returned to normal 
by the sixth month, and over the 6-month period, the implant aver-
age was 0.67 ± 0.19% BW·s larger than the control group animals, 
also indicating better limb use (Fig. 2B). Both implant and control 
groups did not return to baseline for peak propulsion force (PPF) 
and propulsion impulse (PI), but it was noted that the implant group 
was trending toward baseline faster than the control group for both 
measures (Fig. 2, C and D). Although body weight distribution re-
turned to baseline for both implant and control groups, that return 
happened 1 month earlier for the implant group than it did for the 
control group (Fig. 2E). Along with the gait analysis measures, the 
discrepancy in limb girth between operated and unoperated contra-
lateral limb trended toward normal at a faster rate in the implant 
group than the control group, but neither group returned to baseline 
over the duration of the study (Fig. 2F). This finding was confirmed 
by computed tomography (CT) analysis at the end of the study when 
comparing the cross-sectional area of the thigh of the experimental 
limb to the contralateral, unoperated limb. The control animals had 
a −15.3 ± 8.1 cm2 difference (operated minus unoperated) in area, 
and the implant animals had a −5.3 ± 4.3 cm2 difference in area. For 
pain, as measured by the Canine Research Orthopedic Pain Inventory 
(CROPI-h; see also fig. S1), the implant group’s score was 6.82 ± 
2.23 smaller (less pain and impairment) than the control group’s 
average across all time periods, and the dogs receiving the implant 
returned to normal preoperative levels of pain and function by the 
second month of the study (Fig. 2G and fig. S1). Body weight for all 
animals within each group was consistent throughout the study 
period (Fig. 2H).
Overall, the (negative) effect on activity was greater in the con-
trol group than implant group (Fig. 3), with the implant group re-
gaining baseline activity by the end of the first postoperative month 
when examining peak hours of activity (Table 1). Significant treat-
ment effects were observed at each monthly interval (P = 0.0031). 
Significant interactive effects were also noted, particularly month*hour 
(P < 0.05) and treatment*hour (P < 0.0001) as observed by the dif-
ferent trends in the two peaks of activity measured when the animals 
were interacting with the care technicians. Averaged across the 
6-month period, significant differences were noted between the hours 
of 7:00 a.m. and 4:00 p.m.
Variables of time (i.e., month of analysis) and treatment (control 
versus implant) were significant for measured values of gait analysis, 
limb girth, and CROPI-h (Table 1); however, no time/treatment in-
teractive effects were observed in the study. A treatment effect was 
insignificant in only two of the nine measures: static body weight 
distribution and OA radiographic score.
Radiographic scores of OA and synovium histology; 
organ pathology
Ventral-dorsal radiography demonstrated no noticeable issues in the 
implant group, although bone loss and exostosis in ring form were 
Fig. 1. Implant configuration and surgical procedure. (A) The cartilage compo-
nent is constructed of a 3D woven textile, and (B) additive manufacturing is used to 
make a printed base, which, when fused together, form the (C) final bicomponent 
implant (D) 10 mm in diameter by ~2 mm deep. (E) 3D schematic of the woven textile 
demonstrating orthogonality of the structure. (F and G) Scanning electron microscopy 
images demonstrate bonding and encapsulation (black arrow) of woven yarns 
(white arrows) in the first layer of the printed PCL component (black asterisks). 
Scale bars, 100 m. (H) MSC seeding (green fluorescence) is followed by (I) expan-
sion, differentiation, and tissue development ex vivo. (J) Control defect site and 
(K) implant disposition are shown at the time of surgery. (L) A capsulorrhaphy pro-
cedure, standard in the canine model, was used to stabilize the joint. Photo credit: 
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evident in the control group (Fig. 4A). OA radiographic scoring 
indicated normal joint findings for the implant group in months 1 
and 2, while significant differences were noted between preoperative 
values and postoperative radiographic markers for all time points 
following surgery in the control animals (Fig. 4, B and C). Mild 
synovitis was observed on all operated hip joints (Fig. 4, D and E). 
While no significant differences were noted between control and 
implant synovium, trends of higher chronic inflammation and 
synovial hyperplasia, along with more giant cells, were observed in 
the untreated joints than in the implant joints (Fig. 4F). Heart, kidney, 
spleen, lung, liver, and skeletal muscle all showed no aberrant 
pathology, including inflammation. Regional lymph nodes showed 
mild reactive changes, including scattered giant cells that were likely 
related to the surgical procedure, as they were similar in control and 
implant groups.
Cartilage and subchondral bone: Gross and histological 
findings, immunohistological findings, and day 0 
biochemical findings
No depressions were observed in the implant-treated femoral heads 
(Fig. 5, A to C), and the surface of the implant appeared to be 
smooth with no surface irregularities. In contrast, control defects 
showed depressions into the osteochondral bone (Fig. 5, D to F) 
with only fibrous connective tissues in the osteochondral defects 
(Fig. 5G). Cartilaginous tissue ingrowth and overgrowth occurred both 
in and on the woven phase of the bicomponent device (Fig. 5, H and I), 
and a consistent finding was that these tissues appeared to be bonded 
to adjacent cartilage at the periphery of the device with no fissures 
at either end of the device (Fig. 5, J and K). In addition, a limited 
amount of bone integrated with the printed portion of the implant 
was observed with no fissures between the implant and the sur-
rounding bone (Fig. 5, I and M). Tissue filling the pores between the 
poly(-caprolactone) (PCL) printed struts consisted primarily of 
fibrous tissue (Fig. 5L). Microradiographs showed no reduction in 
bone mineral density adjacent to the implant and minimal ingrowth 
into the textile component of the implant (Fig. 5M). Typical cross 
sections of the implant demonstrated fibrous overgrowth, complete 
tissue infilling of the pores in both components of the implant 
(i.e., both textile and printed portions) with the implant intact at this 
6-month terminal time point (Fig. 5N). Rounded chondrocyte-like 
cell morphology within the pore structure of the textile was also 
observed (Fig. 5O). There was no inflammation observed in peri- 
implant tissues. In addition, there were no changes in the histological 
sections of the acetabula in either the control or implant hips. 
Immunohistochemical labeling for collagen types I and II revealed 
fibrous structure in the textile component alone containing both 
collagens at the time of implantation (Fig. 6). The empty defect con-
trol group was completely filled with type I collagen only, while the 
Fig. 2. Gait analysis. Measured kinetic GRF indices including (A) PVF, (B) VI, (C) PPF, and (D) PI (all based on % BW) rapidly returned to baseline in the implant group; 
conversely, the empty defect group kinetic indices never returned to normal. (E) Body weight distribution of the operated limb in standing (measured by a pressure-sensitive 
walkway) showed a return to baseline in both groups. Data are presented as change from baseline, normalized by BW. (F) Change in limb circumference as measured by 
the difference between operated limb and contralateral unoperated limb indicates recovery of muscle volume in the implant group and persistent atrophy in the empty 
defect group, *P < 0.05. (G) Pain scores (CROPI-h) were consistently lower in the implant group compared to the control group; however, no time/treatment interaction 
was observed (P = 0.075). (H) Weights of animals throughout the study. Means ± SD with a two-factor (treatment and time) ANCOVA model were used with responses dijk 
and covariate xij: Overall time and treatment effect P values are noted on figures, no time*treatment interactive effects were observed in any of the measures. # indicates 
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implant contained a mixture of both type I and II collagen at the 
6-month time point. These collagens were found colocalized in 
both the textile and printed components of the implants (Fig. 6). 
Dimethylmethylene blue normalized to double-stranded DNA (dsDNA) 
and hydroxyproline (OHP) normalized to dsDNA revealed sulfated 
glycosaminoglycan (sGAG)/DNA at 12.39 g/g and total collagen/
DNA of 102.1 g/g for day 0 constructs (18).
Modified O’Driscoll scores showed that the control group had the 
greatest reduction in histology scores, whereas the implant group had 
significantly higher scores, indicating histology closer to baseline 
than untreated defects (Fig. 7). Eleven of the 12 unoperated normal 
(i.e., contralateral) femoral heads had a histology score of 20/20 and 
was 18/20 in the other. The range for the control defects was 6 to 9 
and 13 to 14 for the implants. There was a significant difference 
between the two groups (P = 0.0001) for the operated to unoperated 
difference in histology score. The average difference in the control 
group was −13.0 ± 0.63 (SEM), and in the implant group, it was −6.8 ± 
0.17. In comparing the implant to the unoperated cartilage control, 
the implant was not significantly different in five of the eight com-
ponents of this scoring rubric, which included surface irregularity, 
cartilage level, adjacent cartilage bonding, presence of inflammatory 
cells, and chondrocyte clustering. The measures that were significantly 
different were subchondral bone regeneration, freedom from adjacent 
tissue degeneration, and hyalinity (Fig. 7).
Mechanical properties
At the time of implantation, the implants had a mean compressive 
instantaneous modulus of 5.93 MPa with a mean compressive equi-
librium modulus of 4.61 MPa. After 6 months in vivo with significant 
tissue both in and on top of the surface of the implants, both the 
instantaneous and equilibrium moduli of the implant were signifi-
cantly decreased from day 0 values to 0.99 and 0.46 MPa, respectively. 
Significant differences were observed in the mechanical properties 
of the implant repair tissue as compared to control tissue, with a 
greater than 10-fold higher modulus in the implant group (equilib-
rium modulus: 0.460 MPa versus 0.039 MPa for the implant and 
control groups, respectively; instantaneous modulus: 0.99 MPa 
versus 0.293 MPa for the implant and control groups, respectively) 
(P < 0.05). The instantaneous modulus of the contralateral control 
(unoperated) was approximately 4-fold higher than the repair tissue 
with the implant group but was 15-fold higher than the instantaneous 
modulus measured in the empty defect repair tissues (P < 0.0001). 
The equilibrium modulus of the contralateral control cartilage was 
more than 2-fold greater than the repair tissue in the implant group 
(P < 0.05) but was more than 30-fold higher relative to the empty 
defect repair tissue (P < 0.0001) (Fig. 8).
DISCUSSION
The findings of this study show that an anatomically shaped tissue- 
engineered implant consisting of an interconnected 3D woven and 
3D printed composite can provide functional restoration of massive 
osteochondral defects in the hip joint. Excellent integration of this 
MSC-seeded construct was observed in all cases, and no failures were 
observed. Pain and function outcomes in the animals receiving the 
construct showed significant improvement by the first measured 
time point (1 month) and demonstrated a return to normal pre-
operative values by the 6-month time period. The implants showed 
mechanical properties approaching those of normal cartilage, as 
compared to unfilled defects, which showed a compressive modulus 
of less than 10% that of implant tissues.
The primary objective measures used in this study were derived 
from biomechanical analysis to determine the functional response 
of joint restoration following the creation of a massive (10 mm) 
defect in the hip. This massive defect comprised approximately 60% 
of the major load-bearing surface of the femoral head and is much 
larger than what is typically observed in clinical practice. In context, 
the created lesion was approximately twice the size of early clinical 
lesions in this area that are associated with clinical signs of OA in 
dogs. An empty defect alone served as a control for the implant group 
since, clinically, the size of the lesion would not spontaneously heal 
and would also progressively lead to joint degeneration. In addition, 
the bone preparation used was effectively a bone marrow stimulation 
technique that is analogous to techniques that are currently used 
clinically, such as microfracture. Gait analysis has been validated as 
an objective measure of changes in limb use as it relates to joint pain 
in dogs and humans (19, 20). The decrease in kinetic ground reac-
tion forces (GRFs) from baseline to 6 months following surgery 
in the control group was similar to the difference between that in 
Fig. 3. Actimetry data. (A to H) Total activity count expressed as the average per 
minute activity over the preceding 2-week period, shown for each hour of the day 
(at baseline, 1, 2, 3, 4, 5, and 6 months postoperatively). Significant treatment effects 
were observed at each monthly interval (P = 0.0031). Significant interactive effects 
were also noted, particularly month*hour (P < 0.05) and treatment*hour (P < 0.0001) 
as observed by the different trends in the two peaks of activity measured when the 
animals were interacting with the care technicians. (H) Across the 6-month period, 
significant differences were noted between the hours of 7:00 a.m. and 4:00 p.m. 
(*P < 0.05 and +P < 0.0001). The implant group returned to baseline at hours 7 and 
14 in month 1, while the control group never returned to baseline. # indicates no 
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clinically sound dogs and dogs with naturally occurring hip OA, as 
well as that in humans between patients with OA and non-OA 
patients (21). Furthermore, the return toward normal GRFs by 3 to 
6 months following the surgery in the implant group was similar to 
the changes following successful total hip replacement (THR) in dogs 
(19, 22). Seibert and colleagues (22) reported PVF and VI of pet dogs 
with diagnosed OA and undergoing THR. On average, the animals 
with naturally occurring OA had PVF deficits of 7.5% BW relative 
the contralateral limb, similar to the difference between the operated 
and control limbs of the control group (empty defect) dogs (~5% BW). 
THR in pet dogs resulted in a 3.65% BW improvement in limb use 
(with up to 12 months of follow-up), and in our study, the differ-
ence in PVF between the control and seeded group was ~11% BW 
at 6 months. Similarly, VI of the operated limb in pet dogs was in-
creased approximately 1% after hip replacement, also in line with the 
difference between control and seeded scaffold groups at 6 months 
(1%) (22). Together, GRF data obtained in the current study suggest 
equivalent or greater functional outcomes to that which is obtained 
with total hip arthroplasty, which is validating for our approach. It 
is well established that a THR alleviates pain and lameness in the 
canine hip (23), and the fact that we obtained equivalent changes in 
both PVF and VI strongly suggests palliation of pain and lameness, 
which was also confirmed across our measures in the present study. 
Although there were no significant differences between groups, an 
analysis of body weight distribution to the operated limb at 6 months 
following surgery in the implant group was closer to baseline than 
the control (empty defect) group. The increase in the body weight 
distribution of ~10% over the 6-month study in the implant group 
over time is completely consistent with what was observed in a pre-
vious study for dogs with a unilateral THR in dogs (17) and in humans 
that had undergone unilateral total hip arthroplasty (24). Overall, dy-
namic and static GRFs suggest that our biological resurfacing tech-
nique restores limb function following surgery.
Additional measures of the efficacy of this procedure were made 
using activity measurement with accelerometers, which provide a 
validated surrogate measure of movement as a measure of pain and 
function (25) and have successfully been used to detect changes in 
activity related to analgesic therapies in clinical OA studies in dogs 
(26). In the present study, we observed significant reductions in 
activity in the control (empty defect) group, indicative of ongoing 
pain and functional deficits that persisted throughout the 6-month 
study period. However, in the implant group, no significant differ-
ences between baseline and overall postoperative activity levels were 
observed, indicating an absence of pain. In terms of patterns of 
activity, we observed a bimodal pattern, similar to that that has been 
described in research in pet dogs (25, 26). The peaks of activity were 
primarily affected in the present study in the control (empty defect) 
dogs, and these peaks represent more intense activity. The provision 
of effective analgesia (anti–nerve growth factor monoclonal antibody) 
in pet dogs similarly affected these peaks of activity (26). These mea-
surements are consistent with the patterns of reduced activity ob-
served in humans with OA compared to healthy humans (27).
The change from baseline in limb girth, as calculated by the dif-
ference between operated and unoperated contralateral limb, 
mirrored the change from baseline in limb use. In the implant group, 
limb circumference increased as kinetic variables returned to pre-
operative values, whereas the control group’s limb circumference 
never returned to the baseline, matching the reduced limb use. This 
relationship between limb use and muscle mass is similar to what is 
seen in humans (28). The limb girth measurements were supported 
by the objective measurement of thigh muscle cross-sectional area 
using CT, and there was a significant correlation between these two 
measures (r = 0.58, P = 0.0063) at the 6-month time point.
A critical design parameter of the tissue-engineered implant was 
the ability to reproduce the mechanical properties and anatomic 
structure of the cartilage defect from the initial time of implantation. 
Fig. 4. Radiographic and synovial inflammation suggests inhibition of OA progression in the treatment group. Ventral-dorsal radiographic examples demonstrate 
(A) obvious bone loss and exostosis in ring form (white arrows), giving a slight conical appearance of the femoral head in the control animals and (B) what appears to be 
a radiographically healthy joint in the experimental implant group as noted by the absence of any extraarticular bone remodeling. (C) Radiographic OA severity shows a 
significant effect of time (P = 0.0005) but not treatment, although a trend was noted toward a treatment effect at the later time points (P > 0.05; # indicates no difference 
from baseline in the implant group). Histological sections showing (D) severe and (E) mild cases of synovial hyperplasia and chronic inflammation, respectively, with black 
arrows indicating examples of giant cells. H&E histology stain: Scale bars, 0.1 mm. (F) Semiquantitative scoring of synovial tissues (maximum score of 3: normal, 0; mild, 1; 
moderate, 2; and severe, 3) for chronic inflammation severity, synovial hyperplasia severity, and the presence of giant cells. Further details of the scoring matrix are pro-
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These properties were conferred by the 3D orthogonal weaving 
method that was “tuned” to match the implant properties a priori 
(9, 11). Tissue development in the implant served to significantly 
decrease the modulus values relative to day 0, revealing the contri-
bution of the newly synthesized and remodeled tissue on the me-
chanical behavior of the biosynthetic composite. Regardless of the 
relative mechanical contribution of the PCL-based bicomponent 
implant and the newly synthesized tissues, our results confirm the 
restoration of the native anatomical contours with a hybrid biologic/
synthetic implant that exhibited native cartilage compressive values. 
During the culture of the constructs, we only observed filling of the 
textile component with small amounts of de novo tissue (Fig. 6), but 
no tissue was synthesized in the printed component. Accordingly, 
all tissue that is observed in the printed base was synthesized in vivo 
Fig. 5. Gross findings/histology. (A to C) The smooth implant contour typically matched native anatomy (dog 6) (black arrows). Round ligament is visible (black arrowheads). 
(D to F) Empty defects (left to right: dogs 7, 2, and 7) (black arrows) showed significant fibrocartilage filling. (G) Mallory Aniline Blue (MAB) of empty defects (dog 13) 
showed unhealed fibrous-filled depressions (white asterisk − dotted line = ~original articular surface). Inset (millimeter scale): Magnification of defect. (H) Undecalcified 
implant section (dog 6) revealed host tissue integration and a smooth surface without irregularities (black triangle). Trichrome (millimeter scale) (I) with limited new bone 
formation (white asterisk). (J) Undecalcified section (dog 11) (trichrome) demonstrates congruency with native surfaces (black arrowhead). Z-fiber (black arrow) presence 
demonstrates implant integrity. (K) Representative Safranin O/Fast Green staining (dog 12) showed fibrous bonding to adjacent cartilage at defect margins (black arrows) 
(79×). (L) H&E (dog 11) showing fibrous tissue (white asterisk) around PCL struts (79×). (M) Representative microradiograph (dog 11) revealed limited bone formation 
within the base (white arrows). (N) Decalcified histology (dog 6) showed fibrous growth in/on the implant (MAB, 31×) (O) and few chondrocytes (dog 10) in the implant 
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over the 6-month period. The fact that the initial printed base was 
devoid of cells and tissue at day 0 could account for why little bone 
development had occurred in the printed component of the implant, 
and perhaps, future studies using longer survival times may allow 
for this bone tissue development. Immunohistochemical labeling 
for type I and II collagen revealed only type I collagen in the empty 
defects, whereas colocalization of collagen types I and II is present 
in the implant group. These data suggest that the PCL implant is 
inducing (or, at a minimum, is conducive to) a more cartilage-like 
phenotype due to the production of type II collagen. The integra-
tion of this structure with native tissues allowed a seamless transi-
tion from native, preexisting tissue to de novo tissue, such that the 
joint could articulate freely in seemingly a pain-free state as con-
firmed by actimetry, gait analysis, limb girth, and pain assessment. 
Moreover, the mechanical properties also indicate values in the range 
of normal articular cartilage, underscoring the functionality of the 
tissues in the implant group at the 6-month time point. In total, 
these histological and mechanical analyses strongly supported our 
hypothesis that a tissue-engineered anatomically shaped implant 
could restore structure and functional properties of the tissue and 
then, as a consequence, that of the joint.
From a regulatory perspective, the implant used in this study would 
require a Biological License Application as a combination product 
regulated by both the Center for Biologics Evaluation and Research 
and the Center for Devices and Radiologic Health. The work pre-
sented here serves as preliminary data, providing early efficacy data 
on the approach with the bicomponent implant. Longer time points 
and other preclinical work would be required before entering phase 1 
clinical trials.
Despite being the standard of care in hip OA, total joint replace-
ment is not an ideal procedure for the young human patient pop-
ulation presenting with hip degeneration because they would likely 
require multiple revision surgeries in their lifetime, each iteration 
posing additional complications, quicker implant failures, and over-
all decreased satisfaction. Hence, there is a critical need for new in-
terventions that delay or halt the progression of OA and the need for 
initial joint replacement. The approach for using such a construct as 
presented in this manuscript would be to stave off a traditional total 
hip arthroplasty procedure by providing pain relief and restoring an 
active lifestyle in this young and active human patient population. An 
important advantage of the method proposed is that the bioartificial 
implant is expected to integrate with the native bone while preserving 
the integrity of the bony structure of the joint. If, over time, disease 
progresses to the point that total joint replacement is an appropriate 
choice of treatment, then the joint could be readily converted to a 
standard joint replacement procedure. Because little or no bone is 
Fig. 6. Immunohistochemical labeling for collagen I and II at day 0 and after 
6 months in vivo. Scale bars, (day 0 implants) 0.1 mm and (6-month tissues/implants) 
1 mm. Day 0 specimens are both from dog 12. Unoperated cartilage images are from 
the left femoral head of dog 13. Empty defect images are from the right femoral 
head of dog 13, and the implant images are from dog 11.
Fig. 7. Modified O’Driscoll scoring per component and total score. Higher scores indicate better healing. Maximum score is 20 points. Groups not sharing the same 
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removed in the initial implantation of the implant, native bone is 
preserved for resurfacing arthroplasty or total hip arthroplasty pro-
cedures. Consequently, there would be few potential drawbacks as 
compared to an initial joint replacement surgery. Furthermore, be-
cause the components of the implant are bioresorbable, the risk of 
adverse events due to small wear products is greatly reduced. Regard-
ing resorption, the choice of PCL was also deliberate, given its long 
resorptive profile in vivo on the order of years, the bioinert nature 
of the material, and the lack of acidic by-products as it breaks down 
(29, 30). Our expectation, given these characteristics, is that the newly 
synthesized tissue will continue to remodel as more percentage of 
the load is borne by the newly synthesized tissue as the PCL resorbs. 
Longer preclinical studies and, perhaps, even clinical trials will be 
required to fully assess the resorptive nature and functionality of this 
tissue over time.
In summary, all functional outcome metrics including activity 
measurement, dynamic and static gait/standing analysis, and radio-
graphic monitoring demonstrated that the animals receiving the 
implant returned to normal preoperative values by the 6-month time 
period. These functional outcome measures are all highly relevant 
to human patients. Furthermore, the osteochondral defect was placed 
in a clinically relevant, load-bearing position, indicating that the 
implant was able to effectively restore the functional capacity of the 
joint at early times. Although the phenotype of the repair tissue is 
not fully characterized, the data from histology, immunohisto-
chemical, and mechanical analyses, in combination, confirm the 
structural integrity of the implant, its integration with surrounding 
tissues, and the restoration of the articular surface, thereby providing 
a basis and explanation for the functional outcomes that we observed 
in this study. On the basis of the clinically relevant outcome mea-
sures that were investigated, our data provide evidence that a textile- 
based, anatomically shaped resorbable construct can be combined 




All animal procedures were approved by the North Carolina State 
University Institutional Animal Care and Use Committee (#13-010-B). 
Purpose-bred sexually intact male hound dogs (n = 16, 25 to 31 kg) 
were purchased at 2 years of age from an approved vendor. Dogs 
were assigned to a study group if deemed healthy and free of clinical 
orthopedic disease based on clinical examination by a board-certified 
orthopedic surgeon veterinarian, complete blood count, blood 
chemistry, and urinalysis. Bloodwork and urinalysis were also per-
formed before termination. Dogs were sedated and radiographed to 
evaluate for preexisting hip dysplasia, radiographic OA, and closure 
of the proximal femoral growth plates. Following the initial evaluation, 
12 dogs were randomly allocated to either control group (control; 
n = 6) or tissue-engineered scaffold implant group (implant; n = 6). 
The remaining dogs (n = 4) were adopted out because of preexisting 
hip OA and/or behavior incompatibility with study requirements. 
All allocated dogs underwent hip surgery on one side, and the 
contralateral hip was used as the normal control. Surgery was per-
formed on the coxofemoral joint with the least OA and associated 
signs based on clinical assessment and radiography.
Dogs were housed in climate-controlled individual housing with 
room temperature and humidity maintained at 23°C and 30 to 70%, 
respectively. Rooms were on a 12:12 light:dark cycle (light time: 
6:30 a.m. to 6:30 p.m.), with rotating enrichment toys and features. 
The dogs were allowed to move freely inside their runs but were 
acclimated for 2 months before surgery to lowered ceilings to pre-
vent jumping up. The bedding area was placed on the floor with a 
step-up of only 7.6 cm. The dogs were fed according to their caloric 
needs and allowed ad libitum access to water during the study. The 
dogs were walked on leash for 10 min a day until surgery for social-
ization, training to the leash, and enrichment. The dogs were 
transported to the data collection room for 20 to 30 min/day for 
acclimation to performance activities involving the study equipment 
(e.g., trotting across the force plate and standing on the pressure- 
sensitive walkway).
Perioperative management
Preemptive analgesia was provided by a fentanyl patch (75 or 100 g, 
depending on dog weight) applied to the body wall. Dogs were pre-
medicated with acepromazine (0.025 mg/kg, sc) and midazolam 
(0.2 mg/kg, sc). An intravenous catheter was placed, and propofol 
was administered to effect to induce general anesthesia. Anesthesia 
was maintained using isoflurane carried in oxygen and delivered via 
an endotracheal tube and circle circuit. Dogs ventilated spontaneously. 
Vital signs were monitored with electrocardiography, pulse oximeter, 
blood pressure (oscillometry), and capnography throughout 
anesthesia and recovery. Epidural bupivacaine (0.5 mg/kg) and 
preservative-free morphine (0.1 mg/kg) were administered pre-
operatively. Prophylactic antibiotics (cefazolin; 22 mg/kg, iv) were 
given at least 15 min before surgery and then every 90 min during 
surgery. Immediately after surgery, an adhesive bandage and Ioban 
(3M, St. Paul, MN) were applied to the surgical wound and replaced 
as needed until the wound was healed (approximately 5 to 7 days). 
Fig. 8. Instantaneous and equilibrium compressive moduli of implants at day of surgery and after 6 months in vivo. Groups not sharing the same letter are statis-
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Acetaminophen (15 mg/kg, q12h) and gabapentin (10 mg/kg, q12h, 
given orally) were administered postoperatively for 21 days. Addi-
tional analgesia (0.1 to 0.2 mg/kg, sc, of meloxicam or 4.4 mg/kg of 
carprofen orally) was provided if pain was detected on examination 
(M.E. and B.D.X.L.) at any time.
Bone marrow aspiration
Dogs assigned to the implant group had bone marrow aspirated under 
general anesthesia 6 to 8 weeks before surgery. Following aseptic 
preparation of the area, bone marrow was collected from the proxi-
mal humerus using an 11G Jamshidi biopsy needle, and 10 to 15 ml 
of bone marrow were collected into a syringe containing 2000 U of 
heparin. Bupivacaine was injected locally following the procedure, 
and carprofen was administered for a total of 3 days following the 
procedure. Bone marrow was immediately transported on ice to the 
laboratory for subsequent cell cultures.
Tissue-engineered implant
The implant (Fig. 1, A to D) consisted of a novel bicomponent 
structure that combined a biomimetic 3D woven textile (Fig. 1A) for 
reconstructing the cartilage layer with a porous 3D printed structure, 
previously shown to have osteoconductive properties (31). Multi-
filament resorbable PCL yarns (EMS-GRILTECH, Domat, Switzerland) 
measuring ~150 m in diameter were woven in three orthogonal 
directions (x, y, and z directions) using 48 x-direction yarns/cm, 75 
y-direction yarns/cm, and 12 z-direction yarns/cm, resulting in an 
overall porosity of 52.5%. A schematic of the structure is depicted in 
Fig. 1E. The 3D osteoconductive base (Fig. 1B) was manufactured 
by direct extrusion (500 ± 50 m) using a 3D printer (EnvisionTEC 
3D-Bioplotter). The textile and printed phases were bonded using 
localized heat under microscopic guidance to integrate the struc-
tures. More specifically, by taking advantage of the ability of PCL to 
retain heat, the top layer of the additively manufactured base was 
heated to ~65°C, and then the textile is pressed into place to incor-
porate the layers under stereomicroscopic guidance. The resulting 
interface can be seen in Fig. 1 (F and G). Both phases of the implant 
were made using PCL of molecular weight 50 to 60 kDa. The bi-
component woven/printed PCL scaffolds were immersed in a 4 M 
NaOH bath for 15 to 16 hours to clean the fibers and increase their 
surface hydrophilicity.
Cell culture and seeding of scaffold
Collected bone marrow from the initial 10 to 15 ml of aspirate was 
divided between two 50-ml centrifuge tubes, and phosphate-buffered 
saline (PBS) was added to a total of 45 ml of volume per tube. Samples 
were centrifuged for 15 min at 300g to create a pellet of cells. The 
supernatant was aspirated, PBS was added, and the procedure was 
repeated an additional three times until a loose, but clearly identifi-
able, pellet was obtained on the fourth PBS wash. The cell pellets 
were resuspended in 30 ml of MSC expansion media—consisting of 
Dulbecco’s modified Eagle’s medium (DMEM); 10% fetal bovine 
serum; penicillin, streptomycin, and fungizone (P/S/F); and basic 
fibroblast growth factor (1 ng/ml)—and were divided equally among 
three T225 flasks. Expansion media (20 ml) was added to each flask 
to give a final volume of 30 ml per flask. A complete medium ex-
change occurred after 24 hours and then three times per week until 
cells were removed for implant seeding after 1 week. The cells were 
removed using 0.05% trypsin EDTA (5 ml per flask) and incubated 
at 37°C, 5% CO2 for 3 to 5 min. Cells were harvested into 10 ml of 
expansion media and pelleted at 200g for 5 min. The pellet was as-
pirated and resuspended at a concentration of 20 million cells/ml of 
MSC expansion media. Cells were seeded in a 25-l volume to the 
textile surface of the implant, and the scaffolds were placed in the 
incubator (37°C, 5% CO2) and allowed to attach to the 3D woven 
structure for 1 hour, after which the scaffolds were turned upside 
down and 1 ml of media was added to each scaffold. After 2 days, 
another 1 ml of expansion medium was added to the cultures and 
cultured for another 14 days. The cell-seeded implants were sub-
jected to complete media exchanges three times per week irrespec-
tive of medium. After 14 days in expansion medium, the cultures 
were switched to chondrogenic medium consisting of DMEM-HG, 
ascorbic acid (37.5 g/ml), 100 nM dexamethasone, 1× P/S, 
1× insulin/transferrin/selenic acid (ITS+), and transforming growth 
factor–3 (10 ng/ml) for an additional 28 days before implantation.
Surgery
A standard craniolateral approach to the selected coxofemoral joint 
was performed. Following round ligament transection and joint 
dislocation, a 1.1-mm diamond-tip K-wire was inserted into the 
femoral head (midpoint between the round ligament and lateral edge 
of the femoral head), perpendicular to the surface in all directions, 
and to a depth of ~5 mm. A 10-mm-diameter custom-designed 
cannulated end mill with a depth stop was placed over the K-wire, 
and a 2-mm-deep osteochondral defect was created on the dorsal, 
load-bearing aspect of the femoral head. The K-wire was only used 
during the drilling of the defect to stabilize the cannulated end mill 
and was then removed before placement of the implant. The osteo-
chondral defect was then repaired with the cell-seeded scaffold 
(Fig. 1, H to L) in the implant group (Fig. 1K) and left empty in the 
control (empty defect) group (Fig. 1J). The fixation of the implant 
relied on an optimized press interference fit with the prepared de-
fect; no sutures, fibrin glue, or other fasteners were used to stabilize 
the implant in the defect. The joint capsule was closed, and a pros-
thetic capsulorrhaphy was performed (32) using two 3.5-mm 
dorsally placed screws and two strands of fiber wire (Arthrex Inc., 
Naples, FL) placed in a figure-of-eight pattern around each screw 
and through a transosseous tunnel in the intertrochanteric area of 
the femur (Fig. 1L). The capsulorrhaphy was performed so as not to 
impair normal movement of the coxofemoral joint. The dogs were 
allowed unrestrained weight bearing and normal activity in their 
living areas for the first month. From the second month on, range 
of motion (ROM) and leash-walking exercises were instigated. In 
month 2 postoperatively, dogs received 5 min of leash walk and 
30 cycles of ROM exercise on the operated hip joint twice daily. 
During months 3 to 6, dogs received 10 min of leash walk twice 
daily without any passive ROM exercises.
Outcome measures
Gait analysis
Kinetic gait analysis (33, 34) was performed on trotting dogs using 
dual in-series force plates (Advanced Mechanical Technology Inc., 
Watertown, MA) preoperatively and every month following surgery. 
Velocity and acceleration were measured by means of five photo-
metric switches that were connected to the computer analysis sys-
tem and were kept within 1.7 to 2.1 m/s and ± 0.5 m/s2, respectively. 
Five trials were collected from each dog at each time point. A single 
handler and computer operator performed all gait analysis throughout 
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Dewitt, MI) was used to calculate GRFs of the limbs. GRFs were 
expressed in percent body weight. PVF, VI, PPF, and PI were 
analyzed as previously demonstrated (33).
A pressure-sensitive walkway (7100 QL Virtual Sensor 4, Tekscan, 
Boston, MA) was used to measure static GRF data (body weight 
distribution) (17). Static data were acquired as previously described 
(17, 35), preoperatively and every month postoperatively. For each 
dataset, the mean percentage body weight distribution through 
each limb over a steady 5-s period was recorded. Five replicates of 
pressure-sensitive walkway data were acquired for each animal per 
session (once per month) and used for analysis. GRFs (weight) were 
expressed in percent body weight distributed to that limb.
Actimetry
One triaxial, omnidirectional accelerometer (Actical, Philips Respironics, 
Bend, OR) was fixed onto the collar of each dog and worn throughout 
the study to continuously record activity and therefore translational 
movement (25). The recording epoch was set to 1 min, and data were 
downloaded every 4 weeks. Data for the 2 weeks before each outcome 
measure time point were extracted, and the activity over the 2-week 
period was calculated on a per-hour basis by the following equation
  H avg =  
 ∑ j=1 14  ( 
 ∑ i=1 60  c i  _60 ) j
 
  ─14 
where Havg indicates average counts over a specific hour of the day 
over a 2-week period, and Ci  indicates measured counts for each 
minute during the hour.
The times when dogs were removed from their cages for exercise 
were manually recorded cage-side, and activity data from these time 
periods were not included in the analysis. Thus, activity data only 
reflected spontaneous activity in the cage.
Radiography, ROM, and limb girth measurement
Standard extended ventro-dorsal and lateral coxofemoral joint radio-
graphic views and distraction index views (36) were obtained on each 
animal preoperatively and every month for 6 months following surgery 
under sedation with dexmedetomidine (5 g/kg, iv) and butorphanol 
(0.3 mg/kg, iv). All images were anonymized and randomly assigned 
an identification number using a free open source tool (DicomCleaner). 
The ventro-dorsal images were scored for severity of OA by two ex-
perienced blinded observers (consensus scoring), using an 11-point 
(0 to 10) numeric rating scale developed by the research team.
Cross-sectional area of the thigh via CT
Immediately before termination of the dogs, under sedation, CT 
images (SOMATOM Perspective 64, Siemens Medical Solutions USA 
Inc., Malvern, PA) were obtained of both hindlimbs from the cranial 
border of iliac wing to just distal to the toes using a slice thickness of 
1 mm and spacing of 10 mm. Scan parameters were set at 120 to 
130 kilovolt peak and 21 to 129 mA by using a 25-cm field of view, 
a 512 × 512 matrix. Cross-sectional area of the thigh was measured 
at the midpoint of the distance between the most proximal point of 
the greater trochanter and the midpoint of the lateral fabella using 
ImageJ (setting the lower and upper thresholds to −29 and +150). 
The difference in cross-sectional area (in square centimeters) between 
hindlimbs (operated minus unoperated) was calculated in each dog.
Joint motion and muscle circumference
At each data collection time point, circumference (girth) of each thigh 
was measured at point 70% of distance from the great trochanter to 
fabella in the standing dog using Gulick II tape measure (Country 
Technology Inc., Gays Mills, WI). Measurements were obtained in 
triplicate for each limb, and the mean value was used for analysis 
(37). The difference in the limb girth between hindlimbs was calcu-
lated (operated − unoperated).
Pain assessment
The CROPI-h (fig. S1), developed for the assessment of OA-associated 
pain and activity impairment in research dogs, was completed by a 
single observer for each dog preoperatively and every month post-
operatively. A summed score (out of a total of 150) was assigned to 
each dog at each time point.
Histological assessment
Dogs were humanely terminated 6 months after surgery with an over-
dose of pentobarbital sodium and phenytoin sodium (Beuthanasia D 
solution, Schering-Plough Animal Health Corp., Union, NJ). Femora 
and acetabulae were harvested intact, wrapped in PBS-soaked gauze, 
and frozen (−20°C) until analysis.
Joint histology and immunohistochemistry
Implant and control osteochondral defects were transected with a 
low-speed diamond saw such that one-third of the osteochondral 
defect could be processed by decalcified histology and the other 
two-thirds of the defect could be processed by undecalcified histology 
and microradiography. Following decalcification, sections of tissue 
were stained with Alcian blue–periodic acid–Schiff, Safranin O/Fast 
Green, hematoxylin and eosin (H&E), and Mallory Aniline Blue 
connective tissue stain. For acetabula, only H&E decalcified histology 
was performed. For undecalcified histology, plastic-embedded tissue 
blocks were sectioned using low-speed diamond blades to an ap-
proximate thickness of 200 to 300 m. Differential staining using a 
proprietary trichrome stain was performed to permit both histolog-
ical and cytological differentiation. With this staining method, the 
following tissues can be differentiated on the basis of color: Bone is 
stained green, cartilage and fibrocartilage are stained dark purple, 
and fibrovascular tissue is stained pink.
For immunohistochemical analysis, antigen retrieval for sections 
labeled for type II collagen was performed using Digest-All (Life 
Technologies). Antigen retrieval for type I collagen slides was ac-
complished by submerging sections in pH 6.0 citrate buffer, and the 
buffer was brought to a boil in a microwave and then maintained at 
a sub-boiling temperature for 10 min. Monoclonal antibodies were 
used to identify type I collagen (diluted 1:400; rabbit anti–collagen I 
from Cell Signaling Technology, catalog no. 72026) and type II col-
lagen (diluted 1:1; II-II6B3 from Developmental Studies Hybridoma 
Bank, University of Iowa, Iowa City, IA). The secondary antibody 
for type I collagen was the SignalStain Boost IHC Detection Reagent 
[horseradish peroxidase (HRP), rabbit] (Cell Signaling Technology, 
catalog no. 8114). For type II collagen, the secondary antibody was 
the SignalStain Boost IHC Detection Reagent (HRP, mouse) (Cell 
Signaling Technology, catalog no. 8125). Briefly, sections were 
covered with secondary solution (approximately 150 l per section) 
and incubated with the secondary antibody solutions for 1 hour 
at room temperature. A DAB (3,3′-diaminobenzidine) chromogen 
was used for antigen labeling (DAB Substrate Kit, BD Pharmingen, 
catalog no. 550880).
A qualitative assessment of bone healing and cartilage repair was 
made within the osteochondral defects. In addition, a modified scoring 
system based on the O’Driscoll scale (38) (20 points in total) was 
used to evaluate all control femora and osteochondral defects. The 
O’Driscoll scale measured surface irregularity (3 points), cartilage level 
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regenerated subchondral bone (2 points), inflammatory cell in-
flammation around the implant (2 points), chondrocyte clustering 
(2 points), freedom from degenerative changes (3 points), and 
hyalinity (4 points).
Biochemical analysis
A section of day 0 constructs was removed and digested in papain for 
12 hours at 58°C. DNA was measured using the Quant-iT PicoGreen 
dsDNA assay (Life Technologies). sGAG was measured using the 
dimethylmethylene blue assay using chondroitin 4-sulfate as a stan-
dard and reading the optical density on a plate reader (595 nm). For 
total collagen content, OHP was measured by hydrolyzing the digest 
in HCl and reacting the solution with p-dimethylaminobenzaldehyde 
and chloramine-T to measure OHP content per construct. Total 
collagen was then determined using 0.134 as the ratio of OHP to 
collagen (18).
Mechanical testing
Indentation testing was used to measure the compressive modulus 
of the articular cartilage of both the operated and contralateral con-
trol (unoperated) joints, as well as the day 0 implants. A minimum 
of three points were evaluated at the following locations: on the re-
pair tissue, outside of the repair tissue on the treated limb, the con-
tralateral control cartilage in the dorsal, load-bearing region, and on 
the articular surface of the day 0 implants. Indentation testing was 
performed using an ElectroForce testing instrument (TA Instruments, 
New Castle, DE), ensuring normality to the surface, and using a 
spherical 4-mm indenter to perform three compressive stress- 
relaxation steps at 5, 10, and 15% strain steps with a 10-min dwell 
following each step to allow the cartilage and de novo synthesized 
tissues to reach equilibrium. The resulting force-displacement data 
at 10%  were then fit to a viscoelastic indentation model described 
by a modified Hertz equation (39, 40) to determine the instantaneous 
and equilibrium modulus of the tissues.
Pathology assessment
Synovium samples were taken from dorsal, ventral, medial, and lateral 
sections of the operated and contralateral control joints to assess for 
inflammation. Briefly, the tissues were fixed in 10% neutral buffered 
formalin followed by processing for routine paraffin-embedded 
decalcified histology (11). All sections were stained with H&E and 
graded by a trained pathologist (D.J.V.) for chronic inflammation, 
synovial hyperplasia, and the presence of giant cells with a semi-
quantitative four-point scoring system: normal, 0; mild, 1; moderate, 
2; and severe, 3.
Statistical analysis
A longitudinal statistical analysis was performed to compare the 
two treatment groups across the postoperative time points. For the 
operated joint, dijk denotes the difference between the response at 
the kth time point (k = 1,…,6) and its preoperative measurement for 
the jth subject (j = 1,…,6) in the ith treatment group (i = 1, 2). The 
preoperative measurement is denoted xij. For all responses except 
the actimetry data, a two-way analysis of covariance (ANCOVA) 
model was used with responses dijk, covariate xij, and two factors: 
treatment and time. The treatment/time interaction effect was in-
cluded in the model but removed when found to be statistically in-
significant. The covariate effect was included because the range of 
values for dijk and the time required to return to baseline can depend 
on xij. A heterogenous, lag-1 autoregressive [abbreviated as AR(1)] 
covariance structure was assumed that allowed different variances 
for the six time points. For mechanical testing, the raw scores had 
large outliers, so two analysis approaches were taken: a two-sample 
t test using a log transformation and unequal variances and a non-
parametric Wilcoxon test.
Analysis of the actimetry data was performed on dijkl, the lth hourly 
difference between the measurements at time point k and the pre-
operative measurements, xijl. A three-way ANCOVA mixed model 
was fitted, having all main and two-way interactions between the 
factors treatment, time point, and hour as fixed effects and random 
effects for each subject as well as the subject/time point interaction 
effects. The subject/time point interaction random effects were 
assigned a homogenous, AR(1) covariance structure, while the 
residual effects were assumed to have a heterogeneous, AR(1) 
covariance structure.
For each response, we first fit the interaction model described 
above. If the interaction effect was significant, then we reported which 
time points exhibited significant differences between the treatment 
groups and their effect sizes. If the time point/treatment interaction 
effects were insignificant, then the effects were dropped from the 
model, but all other effects were left in the model regardless of their 
statistical significance. Analyses were performed using PROC MIXED 
in SAS 9.4. Statistical tests were performed using the Kenward-Roger 
denominator degrees of freedom method. Statistical significance 
was based on a significance level of 0.05. Post hoc comparisons that 
were performed using Tukey adjustments were used to correct for 
multiple testing.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abi5918
View/request a protocol for this paper from Bio-protocol.
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